University of North Carolina, Lineberger Comprehensive Cancer Center | Strategic Alliance Partners

State of the Science Summit - Leukemia/Lymphoma: Chaired by Deborah Stephens, DO

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Yara Abdou, MD, discusses key updates in breast cancer research, including paradigm shifts on the horizon for trastuzumab deruxtecan, key data regarding capivasertib in the hormone receptor–positive, HER2-negative setting, and the importance of weighing the efficacy benefits of these agents with the risks for serious associated toxicities.

Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.

Catherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.

Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.

Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

Oncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.

Jared Weiss, MD, discusses ​the design of the phase 3 KRYSTAL-10 trial in KRAS G12C-mutated unresectable or metastatic colorectal cancer.

Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.

Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.

Jared Weiss, MD, discusses the rationale for the phase 1/2 KRYSTAL-1 trial in patients with KRAS G12C–mutated colorectal cancer.

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

Catherine Callaghan Coombs, MD, discusses the rationale for the BRUIN study, key efficacy and safety findings, and next steps with pirtobrutinib in chronic lymphocytic leukemia.

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.

Joshua F. Zeidner, MD, discusses the risk of transformation to acute myeloid leukemia in higher-risk myelodysplastic syndromes.

Joshua F. Zeidner, MD, discusses the role that HMAs have played in the MDS treatment landscape and shared data reported with promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets.